Mixed-model repeated-measures models included adjustment for set effects of treatment, baseline worth of the dependent variable, week, treatment-by-week interaction, and prescreening laxative-response position, with center and individual as random effects. Safety analyses were carried out for patients in the intention-to-treat population who had received one or more doses of the study drug. Results Patients Baseline features were balanced across the study groups and were identical between your two studies .AMGA honors Boehringer Ingelheim with Distinguished Corporate Partner Award The American Medical Group Association announced today that it’ll present the AMGA Distinguished Corporate Partner Award on April 16 to Boehringer Ingelheim Pharmaceuticals at its 2011 Annual Conference, 13-16 at the Gaylord National April. The AMGA Distinguished Corporate Partner Award can be presented each year to a nonmedical group company for providing excellent services and worth to medical groupings and their patients. Boehringer Ingelheim Pharmaceuticals was selected to get the 2011 AMGA Distinguished Corporate Partner Award because of its strong and continual support of the association, its applications, and its members. Specifically, AMGA recognized the organization’s support of the Managing Chronic Obstructive Pulmonary Disease Learning Collaborative.